logo

SCIENCE CHINA Life Sciences, Volume 63 , Issue 5 : 774-776(2020) https://doi.org/10.1007/s11427-020-1660-2

Clinical trials for the treatment of coronavirus disease 2019 (COVID-19): A rapid response to urgent need

More info
  • ReceivedFeb 23, 2020
  • AcceptedFeb 28, 2020
  • PublishedFeb 29, 2020

Abstract

There is no abstract available for this article.


Acknowledgment

We thank Dr. Guodong Fang, a former infectious disease professor from the Peking Union Medical College Hospital and senior medical officer at the U.S. Food and Drug Administration, for helpful discussion. We thank Ms. Yu Li for her assistance in data collection. We also thank Dr. Bee Hong Lo, a visiting consultant pediatrician at the Children’s Hospital at Westmead, for editing and proofreading this article.


Interest statement

The author(s) declare that they have no conflict of interest.


Supplement

SUPPORTING INFORMATION

Table S1 Therapeutic approaches in registered clinical trials on coronavirus disease 2019 (COVID-19)

Table S2 Basic information of 125 clinical trials

The supporting information is available online at http://life.scichina.com and https://link.springer.com. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.


References

[1] Chan, K.S., Lai, S.T., Chu, C.M., Tsui, E., Tam, C.Y., Wong, M.M., Tse, M.W., Que, T.L., Peiris, J.S., Sung, J., et al. (2003). Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 9, 399-406. Google Scholar

[2] Chen Y., Guo J.J., Healy D.P., Zhan S.. Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: A meta-analysis. Pharmacy pract (Granada Ed impr), 2007, 5: 1-9 CrossRef Google Scholar

[3] Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506 CrossRef Google Scholar

[4] Maxmen A.. More than 80 clinical trials launch to test coronavirus treatments. Nature, 2020, 578: 347-348 CrossRef PubMed Google Scholar

[5] Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G.. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, : doi: 10.1038/S41422-020-0282-0 CrossRef Google Scholar

  • Figure 1

    Rapidly growing registered clinical trials on COVID-19 in China. A, The curve represents accumulated numbers of COVID-19 cases since January 12, 2020. Daily registered clinical trials numbers are also shown. B, Classification of all 125 clinical trials until February 18, 2020. Among them, four clinical trials tested two treatments each.

Copyright 2020  CHINA SCIENCE PUBLISHING & MEDIA LTD.  中国科技出版传媒股份有限公司  版权所有

京ICP备14028887号-23       京公网安备11010102003388号